General Description

The Diabetes Prevention Program (DPP) is a clinical trial that investigated whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in high risk individuals with prediabetes.

The study enrolled overweight persons with elevated fasting and post-load plasma glucose concentrations. Participants were randomized to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The primary outcome measure was development of diabetes, diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association: a value for plasma glucose of 126 mg per deciliter (7.0 mmol per liter) or higher in the fasting state, or 200 mg per deciliter (11.1 mmol per liter) or higher two hours after a 75-g oral glucose load. Participation in DPP continued after a diagnosis of diabetes was made, although study medication was discontinued and participants were sent to their local primary care provider for treatment of diabetes once fasting glucose was > 140 mg/dl.

Results showed that both lifestyle changes and treatment with metformin reduced the incidence of diabetes in persons at high risk compared with placebo. Furthermore, the lifestyle intervention was more effective than metformin in preventing the onset of diabetes.

Objectives

The primary goal of the DPP study was to compare the efficacy and safety of three interventions—an intensive lifestyle intervention, metformin, or placebo—in preventing or delaying the development of diabetes in high risk individuals. In addition, the study sought to assess differences between the three treatment groups in the development of cardiovascular disease and its risk factors; changes in glycemia, β-cell function, insulin sensitivity, obesity, physical activity, nutrient intake, and health-related quality of life; and occurrence of adverse events.

Outcome Measure

The primary outcome measure was development of diabetes, diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association: a value for plasma glucose of 126 mg per deciliter (7.0 mmol per liter) or higher in the fasting state, or 200 mg per deciliter (11.1 mmol per liter) or higher two hours after a 75-g oral glucose load.
Secondary outcomes included cardiovascular risk profile and disease; and changes in glycemia, β-cell function, insulin sensitivity, renal function, body composition, physical activity, and nutrient intake, and health-related quality of life.

Criteria

Eligibility criteria included:

An age of at least 25 years

A body-mass index of 24 or higher (22 or higher in Asians)

A plasma glucose concentration of 95 to 125 mg/deciliter (5.3 to 6.9 mmol/liter) in the fasting state (≤125 mg/deciliter in the American Indian clinics)

A plasma glucose concentration of 140 to 199 mg/deciliter (7.8 to 11.0 mmol/liter) two hours after a 75-g oral glucose load

Eligible persons were excluded if they were taking medicines known to alter glucose tolerance or if they had illnesses that could seriously reduce their life expectancy or their ability to participate in the trial.

Outcome

The DPP study found that both lifestyle changes and treatment with metformin reduced the incidence of diabetes in persons at high risk; the lifestyle intervention proved more effective than metformin in preventing the onset of diabetes. These results suggest that that type 2 diabetes can be prevented or delayed in high-risk persons through weight loss, a diet low in fat and calories, and regular physical activity.

Study Documents

Persons using assistive technology may not be able to fully access
information in the study documents. For assistance, Contact NIDDK and include
the web address and/or publication title in your message.